Boehringer Ingelheim has won the option to license a cystic fibrosis gene therapy in a collaboration with the UK's Cystic Fibrosis Gene Therapy Consortium and Oxford BioMedica (OXB) to develop an inhaled, lentiviral vector-based treatment. Boehringer will provide funding, along with research and development, to move the therapy through preclinical studies, while OXB will provide expertise in lentiviral-based vector production. Virtual Clinical Trials The new treatment is expected to be available for patients by 2020.
Boehringer Ingelheim has won the option to license a cystic fibrosis gene therapy in a collaboration with the UK's Cystic Fibrosis Gene Therapy Consortium and Oxford BioMedica (OXB) to develop an inhaled, lentiviral vector-based treatment. Boehringer will provide funding, along with research and development, to move the therapy through preclinical studies, while OXB will provide expertise in lentiviral-based vector production. The new treatment is expected to be available for patients by 2020.